Stifel Financial Corp Has $636,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Stifel Financial Corp boosted its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 14.7% in the third quarter, Holdings Channel reports. The fund owned 131,406 shares of the company’s stock after acquiring an additional 16,842 shares during the period. Stifel Financial Corp’s holdings in Verve Therapeutics were worth $636,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Creative Planning acquired a new position in shares of Verve Therapeutics during the 3rd quarter worth about $50,000. PFG Investments LLC bought a new stake in shares of Verve Therapeutics in the third quarter valued at approximately $53,000. Erste Asset Management GmbH acquired a new stake in shares of Verve Therapeutics in the third quarter worth $56,000. Daiwa Securities Group Inc. increased its position in Verve Therapeutics by 89.8% during the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after acquiring an additional 5,723 shares during the period. Finally, Cornercap Investment Counsel Inc. raised its stake in Verve Therapeutics by 13.5% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock valued at $73,000 after purchasing an additional 1,778 shares during the last quarter. 97.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. HC Wainwright decreased their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Canaccord Genuity Group upped their target price on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th.

Verve Therapeutics Trading Down 2.2 %

Shares of VERV opened at $5.77 on Thursday. The stock has a market cap of $488.51 million, a PE ratio of -2.35 and a beta of 1.71. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34. The stock has a 50 day simple moving average of $5.81 and a 200-day simple moving average of $5.67.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm had revenue of $6.87 million during the quarter, compared to analyst estimates of $2.75 million. During the same period in the prior year, the company posted ($0.72) earnings per share. The business’s revenue for the quarter was up 120.2% compared to the same quarter last year. On average, sell-side analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.